Author: Newsdesk

Posted on

PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update

Conference call to be held today at 4:30 p.m. Eastern time

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”) and Solys Diagnostics Inc. (“Solys”) and discussed financial results for the three and nine months ended September 30, 2020.

“During the third quarter of 2020 and subsequent weeks, we have seen commercial activity accelerate as we gain solid traction for PAVmed’s lead products in the medical community,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “Our expanding commercial team has delivered exponential growth in EsoGuard® testing and EsoCheck® procedures, despite the challenges of the pandemic, as well as growing, palpable enthusiasm among physicians for these devices for their potential to save lives through early detection of precursors of highly lethal esophageal cancer. With final U.S. Center for Medicare and Medicare Services (“CMS”) payment determination now secured, we look forward to translating this into a solid, growing revenue stream when CMS payment becomes effective in the New Year.”


RECENT ACCOMPLISHMENTS

  • Secured U.S. Center for Medicare and Medicare Services (“CMS”) Clinical Laboratory Fee Schedule Test Code Final Determination for EsoGuard® Esophageal DNA Test (CPT code 0114U) of $1,938.01, effective January 1, 2021.
  • Expanded sales management team to 5 professionals (CarpX® national sales manager and 4 Lucid regional sales managers) and independent sales network to 38 representatives.
  • Rapidly accelerated EsoGuard testing and EsoCheck procedural activity, doubling their rates approximately every 4-6 weeks.
  • Expanded EsoGuard marketing activities and disease-related educational activities targeting physicians and consumers, including a widely distributed Access Healthsegment aired on the Lifetime Network, highlighting the relationship between Gastroesophageal Reflux Disease (GERD), Barrett’s Esophagus (BE) and highly lethal esophageal cancer (EAC), as well as the role of EsoGuard in early detection and cancer prevention.
  • Received U.S. Patent and Trademark Office trademarks for EsoGuard® and CarpX®.
  • Completed European Union (EU) CE Mark regulatory submission for EsoCheck and confirmed that EsoGuard falls under the self-declaration category of the EU IVDD requirements, clearing the path to European commercialization of both products.
  • Achieved multiple critical PAVmed and Lucid quality management system milestones, including passing stage 2 audits for both, receiving ISO 13485:2016 certification for Lucid and recommendation for certification for PAVmed, clearing the path for EU CE Mark submissions for EsoCheck, CarpX, PortIO™, NextFlo™ and all future PAVmed and Lucid products.
  • Recruited hand surgeon advisory board to perform initial U.S. procedures and serve as trainers, proctors, educators, and ambassadors for the CarpX minimally invasive device to treat carpal tunnel syndrome. Completed initial cadaver training in advance of first U.S. commercial cases.
  • Accelerated enrollment at 21 active U.S. sites for ESOGUARD BE-1 and 2 clinical trials in support of FDA registration of EsoGuard/EsoCheck as an In-Vitro Diagnostic (IVD) device with 33 patients enrolled and tested to date, with no serious adverse events recorded.
  • Completed enrollment in pilot clinical trial evaluating EsoCheck in Eosinophilic Esophagitis (EoE) patients at the University of Pennsylvania.
  • Completed initial diabetic rat model prototype testing of Solys non-invasive glucose monitoring system, achieving R&D plan milestone as defined in license agreement.
  • Continued to expand and advance extensive intellectual property portfolio of 150 issued and pending, owned, assigned or licensed patents across PAVmed and its subsidiaries.
  • Received approximately $7 million in net proceeds from a private placement of Senior Secured Convertible Promissory Notes with an existing institutional investor.


UPCOMING KEY ACTIVITIES AND MILESTONES

  • Initiate claims submission and billing at $1,938.01 for each EsoGuard test performed under CPT code 0114U, effective January 1, 2021.
  • Continue to expand sales management team and independent sales representative network for both EsoGuard/EsoCheck and CarpX.
  • Continue to drive acceleration in EsoGuard testing and EsoCheck procedural activity, targeting both large medical centers and small-medium practices. Continue to optimize sales and training activities as pandemic-related restrictions wax and wane.
  • Perform initial U.S. CarpX procedures by initial cohort of trained experts and subsequently expand clinical and commercial activities to broader group of hand surgeons and other proceduralists.
  • Secure CMS local coverage determinations for EsoGuard and extend payment and coverage process to private payors.
  • Secure EsoCheck and CarpX CE Mark approvals and EsoGuard CE Mark self-certification. Launch EsoGuard, EsoCheck and CarpX in Europe.
  • Accelerate enrollment at U.S. sites for ESOGUARD-BE-1 and 2 screening and case control clinical trials.
  • Launch additional Lucid-sponsored clinical trials of EsoGuard and EsoCheck to support commercial activities including American Foregut Society sponsored EsoGuard Registry, BE EGD Yield study and population study of active measures to enhance BE-EAC screening using EsoGuard.
  • Launch clinical trial of EsoCheck with BE progression markers at Fred Hutchinson Cancer Research Center in Seattle.
  • Continue to explore role of EsoCheck in diagnosing and managing Eosinophilic Esophagitis (EoE) based on results of University of Pennsylvania pilot study and potential EoE biomarkers under development.
  • Complete M&A process and consummate licensing agreement for NextFlo™ technology in disposable infusion pumps.
  • Complete device qualification and FDA 510(k) submission for NextFlo Intravenous Infusion System. Commercially launch NextFlo IV Infusion system at targeted large medical centers following FDA 510(k)-clearance.
  • Secure FDA clearance for an Investigational Device Exemption (IDE) to begin a clinical safety study in the U.S. evaluating PortIO™ Intraosseous Infusion Device in dialysis patients with a one-week implant duration to support its de novo application.
  • Enroll first patients in PortIO long-term clinical study in Colombia, South America to demonstrate up to 60-day maintenance free implant durations in humans.
  • Complete development work and animal testing of EsoCure™ Esophageal Ablation Device in support of FDA 510(k) submission in 2021.
  • Continue to advance development of Solys non-invasive glucose monitoring system towards accuracy milestones sufficient for FDA regulatory submission and commercialization.

FINANCIAL RESULTS

For the three months ended September 30, 2020, research and development expenses were $2.6 million and general and administrative expenses were $2.9 million, in-line with the previous quarter. GAAP net loss attributable to common stockholders was $5.6 million, or $(0.11) per common share. As illustrated below and for the purpose of helping the reader understand the effect of derivative accounting and other non-cash income and expenses on the Company’s financial results, the Company reported a non-GAAP adjusted loss for the three months ended September 30, 2020 of $4.5 million, or $(0.09) per common share.

PAVmed had cash and cash equivalents of $8.3 million as of September 30, 2020, compared with $6.2 million as of December 31, 2019.

The unaudited financial results for the three and nine months ended September 30, 2020 as reported to the SEC on Form 10-Q can be obtained at www.pavmed.com or www.sec.gov.

Non-GAAP Measures

To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.

Non-GAAP financial measures are presented with the intent of providing greater transparency to information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from or as an alternative to, the most directly comparable GAAP financial measures.

Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.

A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2020 and 2019 is as follows:

    For the three months ended September 30,     For the nine months ended September 30,  
(ooo’s except per-share amounts)   2020     2019     2020     2019  
                         
Net income (loss) per common share, basic and diluted     ($ 0.11 )     ($ 0.10 )     ($ 0.57 )     ($ 0.36 )
Net loss attributable to common stockholders       (5,557 )       (3,153 )       (25,751 )       (10,414 )
Preferred Stock dividends and deemed dividends       74         68         215         201  
Net income (loss) as reported       (5,483 )       (3,085 )       (25,536 )       (10,213 )
Adjustments:                                
Depreciation expense1       7         4         17         10  
Interest expense, net3       –         –         53         –  
EBITDA       (5,476 )       (3,081 )       (25,466 )       (10,203 )
                                 
Other non-cash or financing related expenses:                                
Stock-based compensation expense2       586         330         1,458         1,177  
Debt extinguishment3       663         407         4,600         666  
Change in FV convertible debt3       (367 )       (379 )       5,521         341  
Offering costs convertible debt3       50         –         660         –  
Non-GAAP adjusted (loss)       (4,544 )       (2,723 )       (13,227 )       (8,019 )
Basic and Diluted shares outstanding       48,381         31,031         45,564         29,212  
Non-GAAP adjusted (loss) income per share     ($ 0.09 )     ($ 0.09 )     ($ 0.29 )     ($ 0.27 )

1 Included in general and administrative expenses in the financial statements

2 For the three months ended September 30, 2020 includes $448 of stock based compensation expense reported as general and administrative expenses and $138 reported as research and development expense. For the three months ended September 30, 2019 includes $269 of stock based compensation expense reported as general and administrative expenses and $61 reported as research and development expense. For the nine months ended September 30, 2020 includes $1,132 of stock based compensation expense reported as general and administrative expenses and $326 reported as research and development expense. For the nine months ended September 30, 2019 includes $853 of stock based compensation expense reported as general and administrative expenses and $324 reported as research and development expense.

3 Included in other income and expenses

Conference Call and Webcast

The Company will hold a conference call and webcast today at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, President and Chief Financial Officer, will review third quarter 2020 financial results.

To access the conference call, U.S.-based listeners should dial (877) 407-3982 and international listeners should dial (201) 493-6780. All listeners should provide the operator with the conference call name “PAVmed, Inc. Business Update Conference Call” to join. Individuals interested in listening to the live conference call via webcast may do so by visiting the investor relations section of the Company’s website at www.pavmed.com.

Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing (844) 512-2921 from within the U.S. or (412) 317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 13712132. The webcast will be available for replay on the investor relations section of the Company’s website at www.pavmed.com.

About PAVmed

PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical device company employing a unique business model designed to advance innovative products to commercialization rapidly and with less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation while seeking to further expand its pipeline through relationships with its network of clinician innovators at leading academic centers. PAVmed’s diversified product pipeline addresses unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its four operating divisions include GI Health (EsoGuard® Esophageal DNA Test, EsoCheck® Esophageal Cell Collection Device, and EsoCure™ Esophageal Ablation Device with Caldus™ Technology), Minimally Invasive Interventions (CarpX™ Minimally Invasive Device for Carpal Tunnel Syndrome), Infusion Therapy (PortIO™ Implantable Intraosseus Vascular Access Device and NextFlo™ Highly Accurate Disposable Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company’s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Contacts:

Investors

Mike Havrilla
Director of Investor Relations
(814) 241-4138
[email protected]

Media

Shaun O’Neil
Chief Commercial Officer
(518) 812-3087
[email protected]



Posted on

TrustCo continues more than 100-year history of success, announces quarterly dividend

GLENVILLE, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) — The Board of Directors of TrustCo Bank Corp NY (TrustCo, Nasdaq: TRST) today declared a quarterly cash dividend of $0.068125 per share, or $0.2725 per share on an annualized basis. The dividend will be payable on January 4, 2021 to shareholders of record at the close of business on December 4, 2020. TrustCo has paid a cash dividend every year since 1904.

Chairman, President and Chief Executive Officer Robert J. McCormick said: “We are very pleased that our bank’s performance, driven by management’s commitment to the growth of the company, has enabled us to again provide our shareholders with a strong cash dividend. Building on our previous successes and the continued cultivation of new customers in the communities we serve, allows us to deliver this important dividend even in these uncertain times. We are proud to continue the more than 100-year tradition of meeting the expectations of our owners.”

About
TrustC
o
Bank
Corp NY

TrustCo Bank Corp NY is a $5.7 billion savings and loan holding company. Through its subsidiary, Trustco Bank, Trustco operates 148 offices in New York, New Jersey, Vermont, Massachusetts and Florida. Trustco has a more than 100-year tradition of providing high-quality services, including a wide variety of deposit and loan products. In addition, Trustco Bank’s Financial Services Department offers a full range of investment services, retirement planning and trust and estate administration services. Trustco Bank is rated as one of the best performing savings banks in the country. The common shares of TrustCo are traded on the NASDAQ Global Select Market under the symbol TRST. For more information, visit www.trustcobank.com.

Safe Harbor Statement

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended.  Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. TrustCo wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and such forward-looking statements are subject to factors that could cause actual results to differ materially from those discussed. Examples of these factors include, but are not limited to, the effect of the COVID-19 pandemic on our business, financial condition, liquidity and results of operations; the impact of the actions taken by governmental authorities to contain COVID-19 or address the impact of COVID-19 on the economy, and the effect of all of such items on our operations, liquidity and capital position, and on the financial condition of our borrowers and other customers, as well as other financial, operational and legal risks and uncertainties detailed from time to time in TrustCo’s cautionary statements contained in its filings with the Securities and Exchange Commission.

The forward-looking statements contained in this news release speak only as of today’s date. TrustCo disclaims any obligations to update forward-looking statements contained in this news release or in the above referenced reports, whether as a result of new information, future events or otherwise.

Subsidiary: Trustco Bank
   
Contact: Robert M. Leonard
  Executive Vice President and Chief Risk Officer
  (518) 381-3693



Posted on

RM LAW Announces Investigation of Akers Biosciences, Inc.

PR Newswire

BERWYN, Pa., Nov. 17, 2020 /PRNewswire/ — RM LAW, P.C. is investigating potential claims against the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) regarding possible breaches of fiduciary duties and other violations of law related to Akers’ agreement to merge with MYMD Pharmaceuticals, Inc. (“MYMD”).

If you own shares of Akers Biosciences and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.  You may also email Mr. Maniskas at [email protected].  

Under the terms of the agreement, Akers will issue a number of shares of Akers common stock to MYMD’s shareholders. Upon completion of the merger, Akers’ shareholders will own approximately 20% of the combined company and MYMD’s shareholders will own approximately 80% of the combined company.

RM LAW, P.C. is a national shareholder litigation firm.  RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.  To learn more about the class action process, please click here. 


CONTACT:


RM LAW, P.C.


Richard A. Maniskas, Esquire


1055 Westlakes Dr., Ste. 300


Berwyn, PA 19312


 484-324-6800


844-291-9299



[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rm-law-announces-investigation-of-akers-biosciences-inc-301175262.html

SOURCE RM LAW, P.C.

Posted on

Three TrueBlue Leaders Named to SIA’s Global Power 150 – Women in Staffing List 2020

Three TrueBlue Leaders Named to SIA’s Global Power 150 – Women in Staffing List 2020

TACOMA, Wash.–(BUSINESS WIRE)–
TrueBlue is pleased to announce that three of its leaders have been named to Staffing Industry Analysts’ (SIA) list of “Global Power 150 Women in Staffing.” This is the sixth year SIA has released this list, which recognizes female leaders and influencers from around the world and spotlights the contributions and influence of women in the staffing industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117006231/en/

Three TrueBlue leaders have been named to Staffing Industry Analysts’ (SIA) list of “Global Power 150 Women in Staffing.” (Photo: Business Wire)

Three TrueBlue leaders have been named to Staffing Industry Analysts’ (SIA) list of “Global Power 150 Women in Staffing.” (Photo: Business Wire)

The TrueBlue executives featured this year include:

Taryn Owen serves as president of TrueBlue’s industrial staffing powerhouse PeopleReady, which puts nearly 300,000 people to work each year. An innovative leader, Owen is spearheading PeopleReady’s digital transformation in the on-demand staffing arena with its cutting-edge JobStack™ platform—winner of the 2020 top Mobile Site and App Award at the American Business Awards. Before joining PeopleReady, Owen led TrueBlue’s PeopleScout through an era of extraordinary global growth and the launch of its state-of-the-art Affinix™ talent technology. Owen has been widely recognized for her industry leadership with numerous awards, including annual appearances on the Staffing Industry Analysts’(SIA) Staffing 100 list and the HRO Today HR Superstars list. Known for empowering others to create solutions and challenge limits, Owen was named the 2019 Multiplier of the Year for the U.S. She has received a Gold Stevie Award for Female Executive of the Year, a Gold American Business Award for Executive of the Year, a Silver Stevie Award for Woman of the Year – Business Services, a Women World Award for Female Executive of the Year – Business Services—and was named a Woman of the Year by the Golden Bridge Business and Innovation Awards. This is her fourth consecutive year on the list.

Jill Quinn serves as president of Centerline Drivers, a premier driver staffing services company employing more than 4,000 drivers annually. Centerline’s corporate workforce is 60% women and its leadership team is composed of 50% women—one reason Quinn was named one of the Top Women to Watch in Transportation by Women in Trucking (WIT) in 2020. Centerline was also named to WIT’s Top Places for Women to Work in Transportation list in both 2019 and 2020. A longtime promoter of driver safety, Quinn led efforts to ensure drivers were informed and prepared during COVID-19, as Centerline supplied over 10,000 masks along with gloves, hand sanitizer and other cleaning items for its drivers to use to disinfect their truck cabs. Quinn’s dedication to health and safety is matched only by her passion for connecting people to work and building a positive employee culture. An accomplished leader, Quinn took on the additional role of executive leader of PeopleReady Skilled Trades in September 2020. She also sits on the Board of Governors of the National Private Truck Council. This is her third appearance on the list.

Loree Lynch serves as the senior vice president of operations for Staff Management | SMX, which specializes in on-site management of scalable, contingent workforces across North America. A trailblazer in the staffing industry as a founding partner of Staff Management | SMX, Lynch pioneered the idea of on-site staffing and grew it into an international business that connects people and work across North America. As senior vice president in charge of Staff Management | SMX’s Centralized Services function, she combines workforce development, recruiting, onboarding, safety, and data analysis to illustrate to clients how best to staff their supply chain functions—while ensuring that associates have a positive experience from interviewing through hiring and onboarding to their day-to-day work. She helps cultivate positive interactions between associates and the client so that processes run smoothly and productivity remains high. Lynch steered the company through its safety response to COVID-19 for associates, clients and employees. She also leads the company’s work to provide ongoing training and development to all service and management leaders. This is her third consecutive year on the list.

“At TrueBlue, we are fortunate to have incredible women in leadership at every level of our organization—from the frontlines to our executive team,” said Patrick Beharelle, CEO of TrueBlue. “The inclusion of Taryn, Jill and Loree on this prestigious list shows the tremendous impact of these inspiring leaders, and many others like them, both within our company and the industry as a whole. It also emphasizes the importance of continuing to drive greater diversity, equity and inclusion at TrueBlue and throughout the staffing industry.”

“The Global Power 150 – Women in Staffing 2020 are redefining leadership in their decisions, their compassion and their service to their teams and communities,” said Subadhra Sriram, Editor & Publisher, Media Products at SIA. “In a year rife with disruption and with ripple effects disproportionally impacting women and communities of color, this year’s honorees are steadfast in their commitments to diversity and to building resilient and inclusive organizations as they take their businesses, and the ecosystem, forward.”

TrueBlue

TrueBlue (NYSE: TBI) is a leading provider of specialized workforce solutions that help clients achieve business growth and improve productivity. In 2019, TrueBlue connected approximately 724,000 people with work. Its PeopleReady segment offers on-demand, industrial staffing, PeopleManagement offers contingent, on-site industrial staffing and commercial driver services, and PeopleScout offers recruitment process outsourcing (RPO) and managed service provider (MSP) solutions to a wide variety of industries. Learn more at www.trueblue.com.

David Irwin

TrueBlue Communications Director

[email protected]

630-453-1120

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Consulting Women Consumer Professional Services Human Resources

MEDIA:

Photo
Photo
Three TrueBlue leaders have been named to Staffing Industry Analysts’ (SIA) list of “Global Power 150 Women in Staffing.” (Photo: Business Wire)
Posted on

Bank7 Corp. Announces Filing of Shelf Registration Statement

PR Newswire

OKLAHOMA CITY, Nov. 17, 2020 /PRNewswire/ — Bank7 Corp. (NASDAQ: BSVN), the parent company of Oklahoma City-based Bank7, (the “Company”) today announced that it has filed with the Securities and Exchange Commission a $50 million shelf registration statement on Form S-3. 

The shelf registration statement permits the Company to offer and sell, from time to time, in one or more offerings, an indeterminate dollar amount of a variety of its securities, which may consist of common and preferred stock, debt securities, depositary shares, purchase contract, warrants and other securities.  The terms and conditions of any particular offering of securities under the shelf registration statement will be determined at the time of such offering and will be set forth in the applicable prospectus. 

Thomas L Travis, President and CEO of the Company said, “This shelf registration enables us to be timely and efficient when accessing capital markets, providing us maximum flexibility to complete potential strategic opportunities for BSVN.” 

About Bank7 Corp.

We are Bank7 Corp., a bank holding company headquartered in Oklahoma City, Oklahoma. Through our wholly-owned subsidiary, Bank7, we operate nine full-service branches in Oklahoma, the Dallas/Fort Worth, Texas metropolitan area, and Kansas. We are focused on serving business owners and entrepreneurs by delivering fast, consistent and well-designed loan and deposit products to meet their financing needs. We intend to grow organically by selectively opening additional branches in our target markets as well as pursue strategic acquisitions.

Cautionary Statements Regarding Forward-Looking Information

This communication contains a number of forward-looking statements. These forward-looking statements reflect Bank7 Corp.’s current views with respect to, among other things, future events and Bank7 Corp.’s financial performance. Any statements about Bank7 Corp.’s expectations, beliefs, plans, predictions, forecasts, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “believes,” “can,” “could,” “may,” “predicts,” “potential,” “should,” “will,” “estimate,” “plans,” “projects,” “continuing,” “ongoing,” “expects,” “intends” and similar words or phrases. Any or all of the forward-looking statements in (or conveyed orally regarding) this presentation may turn out to be inaccurate. The inclusion of or reference to forward-looking information in this presentation should not be regarded as a representation by Bank7 Corp. or any other person that the future plans, estimates or expectations contemplated by Bank7 Corp. will be achieved.

These forward-looking statements are subject to significant uncertainties because they are based upon:  the amount and timing of future changes in interest rates, market behavior, and other economic conditions; future laws, regulations, and accounting principles; changes in regulatory standards and examination policies, and a variety of other matters.  These other matters include, among other things, the direct and indirect effect of economic conditions on interest rates, credit quality, loan demand, liquidity, and monetary and supervisory policies of banking regulators. Bank7 Corp. has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Bank7 Corp. believes may affect its financial condition, results of operations, business strategy and financial needs. Bank7 Corp.’s actual results could differ materially from those anticipated in such forward-looking statements as a result of risks, uncertainties and assumptions that are difficult to predict. If one or more events related to these or other risks or uncertainties materialize, or if Bank7 Corp.’s underlying assumptions prove to be incorrect, actual results may differ materially from what Bank7 Corp. anticipates. You are cautioned not to place undue reliance on forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made and Bank7 Corp. undertakes no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required by law. All forward-looking statements herein are qualified by these cautionary statements.

Contact:

Thomas Travis

President & CEO
(405) 810-8600

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bank7-corp-announces-filing-of-shelf-registration-statement-301175304.html

SOURCE Bank7 Corp.

Posted on

U.S. Physical Therapy to Present at the 12th Annual Southwest IDEAS Investor Conference

U.S. Physical Therapy to Present at the 12th Annual Southwest IDEAS Investor Conference

HOUSTON–(BUSINESS WIRE)–
U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics (the “Company”),today announced Chris Reading, Chief Executive Officer, and Carey Hendrickson, Chief Financial Officer, will participate in the virtual Southwest IDEAS Investor Conference on Wednesday, November 18, 2020. The Company’s presentation will be webcasted and is scheduled to be available at 7:00 am CST on November 18th. The presentation can be accessed through the Southwest IDEAS conference portal for registered participants and on the IDEAS conference website: www.IDEASconferences.com.

A copy of USPh’s investor presentation is posted on the Company’s website at www.usph.com.

About U.S. Physical Therapy, Inc.

Founded in 1990, U.S. Physical Therapy, Inc. operates 548 outpatient physical therapy clinics in 39 states. The Company’s clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.

More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.

U.S. Physical Therapy, Inc.

Carey Hendrickson, Chief Financial Officer

Chris Reading, Chief Executive Officer

(713) 297-7000

Three Part Advisors

Joe Noyons

(817) 778-8424

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: General Health Other Health Health Fitness & Nutrition Physical Therapy

MEDIA:

Logo
Logo
Posted on

Redfin Survey: 30% of Americans Want to Live Somewhere Else Due to Protests

The share is higher–39%–among respondents who planned to vote for Donald Trump, and 23% of respondents planned to vote for Joe Biden.

PR Newswire

SEATTLE, Nov. 17, 2020 /PRNewswire/ — (NASDAQ: RDFN) — Just under a third (30%) of Americans said that protests in major cities have made them want to move away from where they currently live, or have changed where they want to move to, according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage. The report features survey results from an October Redfin survey of more than 3,000 U.S. residents.

Meanwhile, nearly half (47%) of participants said that protests have had no impact on their feelings about where they live, and almost a quarter (23%) said that such events have made them like where they live more.

“Americans have been leaving major cities in droves during the pandemic, and recent unrest is just one small piece of the puzzle,” said Redfin chief economist Daryl Fairweather. “For some families, the protests, curfews and looting that have taken place in 2020 may have played a role in the decision to leave big-city life behind, but remote work and record-low mortgage rates were likely the driving factors.”

In the late spring of 2020, mass protests broke out in cities across America after a white Minneapolis police officer, Derek Chauvin, killed George Floyd, a 46-year-old Black man. The unrest lasted for weeks in some places, including Seattle’s Capitol Hill neighborhood, where the six-block center of the protests became nationally known as CHOP (Capitol Hill Organized/Occupied Protest).

“Seattle’s condo market has really struggled in general during the pandemic, but the units that are closest to CHOP have typically been selling even more slowly than other condos in Capitol Hill,” said Forrest Moody, a Redfin real estate agent in Seattle. “I had one listing that was a block away from CHOP and across the street from a Ferrari dealership that had its windows smashed. The condo actually sold within five days, but that’s likely because we listed it for $25,000 less than we had planned to back in February.”

In Kenosha, WI, home touring slowed after the Aug. 23, 2020 police shooting of Jacob Blake set off protests downtown, but the city’s housing market has mostly returned to normal, according to local Redfin real estate agent Melissa Killham.

“The protests impacted the market for a few weeks. I heard about a couple of buyers a month ago who realized they wanted to get out of downtown Kenosha because of the unrest,” Killham said. “But now things have died down and you just don’t hear about it as much anymore.”


Respondents in urban areas were more likely to say that protests have made them want to live somewhere else

When broken down by location, respondents living in urban areas were the most likely to say that protests have made them want to live somewhere else. More than a third (34%) of participants residing in urban areas indicated that protests have made them want to move away from where they currently live, or have changed where they want to move to. That compares with 26% of participants living in suburban areas.

Meanwhile, 28% of respondents living in rural areas said that protests have made them like where they live more, compared with 24% of participants living in suburban areas, and 20% of participants living in urban areas.


Trump voters were more likely than Biden voters to say that protests have made them want to live somewhere else

When broken down by which candidate respondents said they intended to vote for, Trump voters were more likely to say that protests have impacted where they want to live. Of the survey participants who indicated that they planned to vote for Trump, 39% said that protests in major cities have made them want to move away from where they currently live, or have changed where they want to move to. That compares with about a quarter (23%) of participants who indicated that they planned to vote for Biden.

To view the full report, including charts and methodology, please visit: https://www.redfin.com/news/housing-market-survey-moving-protests/

About Redfin
Redfin (www.redfin.com) is a technology-powered residential real estate company, redefining real estate in the consumer’s favor in a commission-driven industry. We do this by integrating every step of the home buying and selling process and pairing our own agents with our own technology, creating a service that is faster, better and costs less. We offer brokerage, iBuying, mortgage, and title services, and we also run the country’s #1 real estate brokerage search site, offering a host of online tools to consumers, including the Redfin Estimate. We represent people buying and selling homes in over 90 markets in the United States and Canada. Since our launch in 2006, we have saved our customers over $800 million and we’ve helped them buy or sell more than 235,000 homes worth more than $115 billion.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/redfin-survey-30-of-americans-want-to-live-somewhere-else-due-to-protests-301175297.html

SOURCE Redfin

Posted on

GOHEALTH, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that it has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against GoHealth, Inc.

IMPENDING LEAD PLAINTIFF DEADLINE IS THIS FRIDAY, NOVEMBER 20, 2020

NEW YORK and CHICAGO, Nov. 17, 2020 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a federal securities class action lawsuit against GoHealth, Inc.  (“GoHealth” or the “Company”) (NASDAQ: GOCO).   The class action, filed in United States District Court for the Northern District of Illinois, Eastern Division, and docketed under 1:20-cv-05765, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth’s July 2020 initial public offering (the “IPO”). Wolf Haldenstein is seeking to pursue remedies under the Securities Act of 1933 (the “Securities Act”) against GoHealth, certain of GoHealth’s officers and directors, and the private equity sponsor of the IPO and its affiliates.

All
i
nvestors
who
purchased
shar
es
of
GoHealth
a
nd
incurred losses
a
re
u
rged
to contact the firm
i
mmediately at

[email protected]

or (800) 575-0735 or (212) 545-4774.
You may o
btain additional information conc
erning the action
or

join the case

on our
website
,

www.whafh.com


.

If you have incurred losses in the shares of against GoHealth,youmay,nolater than November 20, 2020, request that the Court appoint you lead plaintiff of the proposed class.   Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of GoHealth.


CLICK HERE TO JOIN CASE

On June 19, 2020, GoHealth filed a registration statement with the United States Securities and Exchange Commission (“SEC”) for the IPO on Form S-1 (the “Registration Statement”), which was used to sell to the investing public 43.5 million shares of GoHealth Class A common stock at $21 per share, for total gross proceeds of $913.5 million.

Our complaint alleges that the Offering Materials for the IPO were negligently prepared and, as a result, contained untrue statements of material fact, omitted material facts necessary to make the statements contained therein not misleading, and failed to make necessary disclosures required under the rules and regulations governing their preparation. Specifically, the Offering Materials failed to disclose that at the time of the IPO:

  • the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020;
  • GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base;
  • GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and GoHealth’s efforts to expand into new geographies, develop new carrier partnerships and worsening product mix;
  • GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and
  • these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the IPO.

Since the July 2020 IPO, the price of GoHealth Class A common stock has suffered significant price declines. By September 15, 2020, GoHealth Class A common stock closed at just $12.53 per share – over 40% below the $21 per share price investors paid for the stock in the IPO nearly two months prior.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



Posted on

ATTO Technology Unveils ATTO SiliconDisk™ RAM-Based Ethernet Fabric-Connected Storage Appliance with <600 Nanosecond Latency

100X faster than flash, SiliconDisk represents a new tier in the storage pyramid

AMHERST, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) — ATTO Technology, Inc., a global leader of network, storage connectivity and infrastructure solutions for data-intensive computing environments for over 30 years, has unveiled ATTO SiliconDisk™, a new, no-compromise storage solution that combines cutting-edge speed and performance with the flexibility and sharing capabilities of Ethernet connectivity.

ATTO SiliconDisk is a scalable, state-of-the-art RAM-based storage appliance that is 100 times faster than flash-based storage solutions. Designed to be quickly set up for access by multiple servers, SiliconDisk far exceeds current SSD solutions for performance and extensibility with under 600 nanoseconds of latency, four 100Gb Ethernet ports and 25GB/s of sustained throughput. Best of all, SiliconDisk requires no special software, no application changes and no re-architecting of data centers, just plug and play.

System architects recognize that there’s a storage performance gap even with flash technology, which is fast but not enough to overcome the challenges modern data loads impose. ATTO SiliconDisk represents a new tier in the storage pyramid, addressing the gap between RAM and traditional storage.

“SiliconDisk is similar in concept to the very first SCSI product ATTO released as a start-up 32 years ago,” said Timothy J. Klein, president and CEO, ATTO Technology. “Of course, this one is far better, faster and this time it’s shareable. We are quite excited about this new product line.”

By bridging that gap SiliconDisk becomes essential for next-generation data processing:

  • increases performance predictability under peak loads
  • provides guaranteed ultra-low latency for critical applications
  • RAM-based persistent storage boosts processing and performance capabilities

Data is instantly stored and retrieved making the SiliconDisk ideal for accelerating real-time data analytics. Artificial intelligence and machine learning, financial trading and medical imaging applications can capture and analyze data instances 100x faster than before. Every node on a high-availability shared fabric can have access to RAM-level storage data.

SiliconDisk is the first and only 1U DRAM-based solid-state storage appliance with multiple 100GbE port connectivity. The four channels of ultra-fast 100GbE are integrated into a single chip and linked to high-speed RAM, all managed by ATTO xCORE™ storage controller technology to eliminate all bottlenecks in performance.

Completing the package of exclusive, built-in technologies are ATTO RToptimizer™ and ATTO Infinite Write Endurance™. RToptimizer delivers real-time performance analytics of storage network connections, storage utilization, as well as overall SiliconDisk data performance for quick and accurate solution optimization. With Infinite Write Endurance, RAM used in SiliconDisk has no “per write” flash performance penalties or worry of memory wear-out.

Glimpse the future of storage architectures by visiting www.atto.com/products/silicondisk for complete details.

Contact ATTO today to schedule a demo of SiliconDisk.

Purchase ATTO products through leading Value Added Resellers, System Integrators and the ATTO Web Store. Learn more: www.atto.com/howtobuy/

Follow ATTO on Twitter, LinkedIn, Instagram and Facebook (@ATTOTechnology).

ABOUT ATTO

For over 30 years ATTO Technology, Inc. has been a global leader across the IT and media & entertainment markets, specializing in network and storage connectivity and infrastructure solutions for the most data-intensive computing environments. ATTO works with customers and partners to deliver end-to-end solutions to better store, manage and deliver data, often as an extension of their design teams. ATTO manufactures host adapters, smart NICs, storage appliances and controllers, intelligent bridges, Thunderbolt™ adapters, and software. ATTO solutions provide a high level of connectivity to all storage interfaces, including Fibre Channel, SAS, SATA, iSCSI, Ethernet, NVMe and Thunderbolt. ATTO is the Power Behind the Storage.

All trademarks, trade names, service marks and logos referenced herein belong to their respective companies.

Contact: Richard Root
ATTO Technology, Inc.
[email protected]
Phone: +1 (716) 691-1999 x285
Fax: +1 (716) 691-9353  


Posted on

Walgreens Wins 2020 Citizens Award for Get a Shot. Give a Shot. Program

Walgreens Wins 2020 Citizens Award for Get a Shot. Give a Shot. Program

Eight-year Collaboration with UN Foundation has Provided 60 Million Immunizations to Vulnerable Populations Around the World

DEERFIELD, Ill.–(BUSINESS WIRE)–
Walgreens announced today that the company has won the “Health and Wellness” category in the U.S. Chamber of Commerce Foundation 2020 Citizens Awards. The annual awards highlight how businesses are helping solve today’s greatest challenges and spearheading the transformation to a strong, healthy and sustainable future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117006217/en/

(Photo: Business Wire)

(Photo: Business Wire)

Walgreens was recognized for Get a Shot. Give a Shot., the company’s eight-year collaboration with the United Nations Foundation, which has helped provide close to 60 million lifesaving vaccines to children in need around the world. For each immunization given at a Walgreens or Duane Reade store or clinic, Walgreens donates the value of an immunization to the UN Foundation’s Shot@Life campaign.

“The collaboration between Walgreens and the UN Foundation demonstrates the power of partnership to maximize impact and reach,” said Marc DeCourcey, senior vice president of the U.S. Chamber of Commerce Foundation. “It’s an honor to showcase their work to build stronger, healthier communities around the world.”

Walgreens has pledged to help provide an accumulated total of 100 million vaccines by 2024, through Get a Shot. Give a Shot. Click here to read more about the impact of the program.

“Walgreens is honored to receive this award, which would not be possible without the support of our patients, customers and team members. Together, and in collaboration with the UN Foundation, this campaign has helped in reducing cases of measles and polio among some of the world’s most vulnerable populations, and furthers our efforts to promote the health and well-being of communities around the world,” said Alex Gourlay, co-chief operating officer of Walgreens Boots Alliance (WBA), parent company of Walgreens.

Funds from Get a Shot. Give a Shot. are donated to Shot@Life to help provide vaccines for children in countries including Afghanistan, Central African Republic, Chad, Democratic Republic of the Congo, East Timor and Tanzania.

“I am thrilled to see Get a Shot. Give a Shot. recognized for its incredible impact,” said Elizabeth Cousens, president and chief executive officer of the United Nations Foundation. “Every child deserves a shot at a happy and healthy life, and we are proud to help provide lifesaving vaccines to millions of children around the world. It’s also a powerful example of what companies like Walgreens can achieve when they mobilize behind the United Nations’ Sustainable Development Goals – which will be central to how we recover from the current health crisis stronger.”

The current Get a Shot. Give a Shot. program lasts through Dec. 31, 2020 and all immunizations administered at Walgreens during this time period are eligible for the program*.

The UN Foundation’s Shot@Life campaign educates, connects, and empowers individuals to champion global vaccines as one of the most effective ways to save the lives of children around the world. The campaign rallies members of the public, members of Congress, businesses, and civil society partners to support and invest in the global childhood immunization programs of UNICEF, World Health Organization, and Gavi, the Vaccine Alliance. Through public education, grassroots advocacy, and fundraising, Shot@Life strives to avert the 1.5 million annual vaccine-preventable child deaths.

WBA and its businesses around the world are committed to improving societal health and wellbeing around the world. Read more about Corporate Social Responsibility at WBA here.

* From 9/1/20 until 12/31/20, for every immunization administered, Walgreens will donate $0.23 to the United Nations Foundation, up to a maximum donation of $2,600,000.

About Walgreens

Walgreens (www.walgreens.com) is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail and wholesale pharmacy. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and wellbeing of every community in America. Operating more than 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 8 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with platforms bringing together physical and digital, supported by the latest technology to deliver high-quality products and services in local communities nationwide.

About United Nations Foundation

The UN Foundation brings together ideas, people, and resources to help the United Nations drive global progress and tackle urgent problems. Our hallmark is to collaborate for lasting change and innovate to address humanity’s greatest challenges. Learn more at www.unfoundation.org

About Shot@Life

Shot@Life is a grassroots advocacy campaign of the United Nations Foundation that champions global childhood immunization as one of the most effective ways to save the lives of children around the world. We rally members of the public, members of Congress, businesses, and civil society partners — through public education and grassroots advocacy— to support and invest in the global childhood immunization programs. Learn more at www.ShotAtLife.org.

Fiona Ortiz

[email protected]

http://news.walgreens.com

@WalgreensNews

facebook.com/Walgreens

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Other Health Pharmaceutical Philanthropy Specialty Consumer Convenience Store Infectious Diseases Fund Raising Retail Seniors Other Philanthropy Health

MEDIA:

Logo
Logo
Photo
Photo
(Photo: Business Wire)